R
Ryuzo Ueda
Researcher at Aichi Medical University
Publications - 600
Citations - 29381
Ryuzo Ueda is an academic researcher from Aichi Medical University. The author has contributed to research in topics: Leukemia & Hepatitis B virus. The author has an hindex of 87, co-authored 589 publications receiving 27813 citations. Previous affiliations of Ryuzo Ueda include Nagoya University & Nagoya City University.
Papers
More filters
Journal ArticleDOI
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
Yukiya Yamamoto,Hitoshi Kiyoi,Yasuyuki Nakano,Ritsuro Suzuki,Yoshihisa Kodera,Shuichi Miyawaki,Norio Asou,Kazutaka Kuriyama,Fumiharu Yagasaki,Chihiro Shimazaki,Hideki Akiyama,Kenji Saito,Miki Nishimura,Toshiko Motoji,Katsuji Shinagawa,Akihiro Takeshita,Hidehiko Saito,Ryuzo Ueda,Ryuzo Ohno,Tomoki Naoe +19 more
TL;DR: Analysis of the mutation of D835 of FLT3, which corresponds to D816 of c-KIT, in a large series of human hematologic malignancies demonstrates that the FLT 3 gene is the target most frequently mutated to become constitutively active in AML.
Journal ArticleDOI
Prognostic Implication of FLT3 and N- RAS Gene Mutations in Acute Myeloid Leukemia
Hitoshi Kiyoi,Tomoki Naoe,Yasuyuki Nakano,Shohei Yokota,Saburo Minami,Shuichi Miyawaki,Norio Asou,Kazutaka Kuriyama,Itsuro Jinnai,Chihiro Shimazaki,Hideki Akiyama,Kenji Saito,Hakumei Oh,Toshiko Motoji,Eijiro Omoto,Hidehiko Saito,Ryuzo Ohno,Ryuzo Ueda +17 more
TL;DR: The FLT3 gene mutation, whose presence is detectable only by genomic polymerase chain reaction amplification and gel electrophoresis, might serve as an important molecular marker to predict the prognosis of patients with AML.
Journal ArticleDOI
Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study
Takashi Ishida,Tatsuro Joh,Naokuni Uike,Kazuhito Yamamoto,Atae Utsunomiya,Shinichiro Yoshida,Yoshio Saburi,Toshihiro Miyamoto,Shigeki Takemoto,Hitoshi Suzushima,Kunihiro Tsukasaki,Kisato Nosaka,Hiroshi Fujiwara,Kenji Ishitsuka,Hiroshi Inagaki,Michinori Ogura,Shiro Akinaga,Masao Tomonaga,Kensei Tobinai,Ryuzo Ueda +19 more
TL;DR: KW-0761 demonstrated clinically meaningful antitumor activity in patients with relapsed ATL, with an acceptable toxicity profile, and further investigation of KW-761 for treatment of ATL and other T-cell neoplasms is warranted.
Journal ArticleDOI
VCAP-AMP-VECP Compared With Biweekly CHOP for Adult T-Cell Leukemia-Lymphoma: Japan Clinical Oncology Group Study JCOG9801
Kunihiro Tsukasaki,Atae Utsunomiya,Haruhiko Fukuda,Taro Shibata,Takuya Fukushima,Yoshifusa Takatsuka,Shuichi Ikeda,Masato Masuda,H Nagoshi,Ryuzo Ueda,Kazuo Tamura,Masayuki Sano,Saburo Momita,Kazunari Yamaguchi,Fumio Kawano,Shuichi Hanada,Kensei Tobinai,Masanori Shimoyama,Tomomitsu Hotta,Masao Tomonaga +19 more
TL;DR: It is suggested that VCAP-AMP-VECP might be a more effective regimen at the expense of higher toxicities, providing the basis for future investigations in the treatment of ATLL.
Journal Article
Prognostic Significance of p53 Mutations and 3p Deletions in Primary Resected Non-Small Cell Lung Cancer
Yoshitsugu Horio,Takashi Takahashi,Tetsuo Kuroishi,Kenji Hibi,Suyama M,Niimi T,Kaoru Shimokata,Kazuhiro Yamakawa,Yusuke Nakamura,Ryuzo Ueda +9 more
TL;DR: The presence of the p53 mutation was associated with a shortened survival in all patients, including those in early stages of the disease, and patients with 3p deletion tended to have a poorer prognosis, but not to a statistically significant extent.